Document Detail


Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
MedLine Citation:
PMID:  23341364     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Burkitt lymphoma (BL) is caused by translocation of the MYC gene to an immunoglobulin locus resulting in its constitutive expression depending on the activity of the immunoglobulin (Ig) enhancer elements. Treatment of BL cell lines with epigenetic modifiers is known to repress B-cell-specific genes and to up-regulate B-cell-inappropriate genes including the transcription repressor ID2 expression. We found that the DNA methyltransferase inhibitor decitabine/5-aza-2-deoxycytidine (5-aza-dC) represses the MYC oncogene on RNA and protein levels by inducing ID2. Down-regulation of MYC was associated with repression of transcriptional activity of the Ig locus and with inhibition of proliferation. The induction of ID2 can be in part explained by activation of the transcription factor NF-κB. We conclude that up-regulation of ID2 contributes to anti-tumour activity of 5-aza-dC via repression of Ig locus activity and consequently MYC expression.
Authors:
Hanfeng Guan; Linka Xie; Kay Klapproth; Clarissa D Weitzer; Thomas Wirth; Alexey Ushmorov
Related Documents :
24980824 - Silencing of line-1 retrotransposons contributes to variation in small noncoding rna ex...
23195574 - Activation of il-1β and tnfα genes is mediated by the establishment of permissive chr...
23999864 - Hormonal modulators of glial abca1 and apoe levels.
24943844 - Sumoylation of gps2 protein regulates its transcription-suppressing function.
20881014 - Hydroureternephrosis due to loss of sox9-regulated smooth muscle cell differentiation o...
24358134 - Ras and rac1, frequently mutated in melanomas, are activated by superoxide anion, modul...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-02-22
Journal Detail:
Title:  The Journal of pathology     Volume:  229     ISSN:  1096-9896     ISO Abbreviation:  J. Pathol.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-15     Completed Date:  2013-05-02     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0204634     Medline TA:  J Pathol     Country:  England    
Other Details:
Languages:  eng     Pagination:  775-83     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Affiliation:
Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimetabolites, Antineoplastic / pharmacology*
Azacitidine / analogs & derivatives*,  pharmacology
Burkitt Lymphoma / enzymology,  genetics*,  metabolism,  pathology
Cell Line, Tumor
Cell Proliferation / drug effects
DNA Modification Methylases / antagonists & inhibitors*
Dose-Response Relationship, Drug
Epigenetic Repression
Gene Expression Regulation, Neoplastic
Humans
Immunoglobulin M / genetics,  metabolism
Inhibitor of Differentiation Protein 2 / genetics,  metabolism
NF-kappa B / metabolism
Proto-Oncogene Proteins c-myc / genetics*,  metabolism
Transcription, Genetic
Transfection
Translocation, Genetic / drug effects*
Up-Regulation
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/ID2 protein, human; 0/Immunoglobulin M; 0/Inhibitor of Differentiation Protein 2; 0/MYC protein, human; 0/NF-kappa B; 0/Proto-Oncogene Proteins c-myc; 320-67-2/Azacitidine; 776B62CQ27/decitabine; EC 2.1.1.-/DNA Modification Methylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Telomere/Telomerase Binding Factor PinX1 is a New Target to Improve the Radiotherapy Effect of E...
Next Document:  The Swedish national public health policy report 2010.